Your Health, We Care
Release date: 2026-02-11 17:28:18 Article From: Lucius Laos Recommended: 5
Medicines are sometimes used for purposes other than those listed in the patient information leaflet. Do not use Tagrisso for unprescribed purposes. Do not give it to others even if they have the same symptoms as you, as it may cause harm to them. For information about Tagrisso intended for healthcare professionals, consult your healthcare provider or pharmacist.
Tagrisso® (Osimertinib Mesylate Tablets) may cause serious side effects, including:
Tagrisso may cause severe, even fatal, lung problems. Symptoms may be similar to those of lung cancer. Immediately inform your healthcare provider if you develop any new or worsening lung symptoms, including difficulty breathing, shortness of breath, cough, or fever.
Including heart failure, Tagrisso may cause heart problems, even fatal. Your healthcare provider should check your heart function before you start taking Tagrisso and during treatment as needed. Immediately inform your healthcare provider if you develop any of the following heart problem symptoms: a racing or pounding heartbeat, shortness of breath, swelling of the ankles or feet, dizziness, light‑headedness, or fainting.
Lucius Pharmaceuticals Tagrisso may cause eye problems. Immediately inform your healthcare provider if you develop eye problem symptoms, including watery eyes, sensitivity to light, eye pain, redness of the eye, or vision changes. If you develop eye problems while taking Tagrisso, your healthcare provider may refer you to an ophthalmologist.
Store Lucius Pharmaceuticals Tagrisso at room temperature 68°F to 77°F (20°C to 25°C).
Safely dispose of any expired or no longer needed medicine.
Keep Tagrisso and all medicines out of the reach of children.
The above is general information for the safe and effective use of Tagrisso.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1022025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3802024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：902025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1122025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1072025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1212025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1172025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1132025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
